Novel Pharmacological Approaches for Neuroprotection in Acute Stroke View PDF

The pursuit of novel pharmacological approaches for neuroprotection in acute stroke has garnered significant attention, as evidenced by recent comprehensive reviews and experimental studies [1-3]. Paul and Candelario-Jalil [4] highlight the complexity of stroke pathology, emphasizing the need for innovative neuroprotective strategies that address both ischemic and hemorrhagic subtypes. Their overview underscores the challenges faced in translating preclinical neuroprotectants into clinical success, while also noting ongoing initiatives such as the stroke preclinical assessment network aimed at identifying promising candidates. Emerging pharmacological agents are being evaluated across various phases of stroke management. Safouris et al. [5] discuss several agents under clinical trial, including nerinetide, which shows promise as a neuroprotective agent, and tenecteplase, an alternative thrombolytic to alteplase. Additionally, glibenclamide is being investigated for its potential to reduce edema in malignant hemispheric infarction, illustrating a multifaceted approach to neuroprotection that extends beyond thrombolysis.

Preclinical studies have explored innovative molecular targets and compounds. Zhang et al. [6] introduced a novel metformin derivative, metformin threonate (SHY-01), which has demonstrated efficacy in improving functional recovery post-ischemia. Similarly, Ayuso-Dolado et al. [7] designed cell-penetrating peptides targeting calpain-mediated cleavage of PSD-95, a process implicated in excitotoxic neuronal damage, suggesting a targeted molecular approach to neuroprotection. Non-pharmacological strategies are also gaining traction as adjuncts or alternatives to traditional drug therapies. Buetefisch et al. [8] investigated low-frequency repetitive transcranial magnetic stimulation (rTMS), revealing its potential to confer neuroprotection when applied acutely after stroke. Complementing this, Chen et al. [9] demonstrated the efficacy of targeted hypothermic neuroprotection via autologous blood transfusion in a non-human primate model, highlighting a novel approach to mitigate ischemic injury during reperfusion.

Furthermore, the modulation of intracellular signaling pathways and neuroinflammation remains a promising avenue (Figure 1) [10]. Wolska et al. [11] reviews the role of long non-coding RNAs in ischemic stroke, suggesting that these molecules could serve as therapeutic targets or biomarkers for neuroprotection. The integration of such molecular insights with pharmacological interventions could enhance the specificity and efficacy of future therapies. In summary, recent research underscores a diverse array of novel pharmacological and adjunctive approaches for neuroprotection in acute stroke. These include targeted molecular therapies, innovative drug derivatives, and non-invasive neuromodulation techniques, all aimed at reducing neuronal damage and improving functional outcomes. Continued interdisciplinary efforts and rigorous clinical evaluation are essential to translate these promising strategies into effective treatments for stroke patients [4, 5].

Stroke remains a leading cause of mortality and long-term disability worldwide, necessitating the exploration of innovative pharmacological strategies for neuroprotection. Acute ischemic stroke is characterized by the sudden blockage of blood flow to the brain, leading to neuronal death and functional impairment. Despite advancements in reperfusion therapies, the need for effective neuroprotective agents remains critical to mitigate brain damage and improve patient outcomes